HIV/AIDS Medications: Research on Isentress
- Safety of Transplacental Raltegravir in Neonates and Washout Pharmacokinetics (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Raltegravir Shows Long-Term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection (September 20, 2012)
From HIVandHepatitis.com
- Skeletal Muscle Toxicity and Raltegravir (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Dolutegravir vs. Raltegravir in Treatment-Naive Patients: 48-Week Results From the SPRING 2 Study (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Elvitegravir vs. Raltegravir: 96-Week Phase III Results in Treatment-Experienced Patients (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Five-Year Results From Raltegravir Registrational Studies (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Raltegravir Remains Effective and Well-Tolerated at 5 Years (August 7, 2012)
From HIVandHepatitis.com
- Gilead HIV Drug as Good as Merck's Isentress: Study (August 2, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- AIDS 2012: Other Treatment Studies (August 1, 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Raltegravir 800 mg Twice Daily Appears a Good Alternative to Efavirenz for HIV-TB Treatment (July 31, 2012)
From aidsmap.com
- Washout Pharmacokinetics of Transplacental Raltegravir in Neonates (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 SPARTAN: Two-Drug, NRTI-Sparing Strategies Continue to Disappoint (June 8, 2012)
From Journal Watch
On TheBodyPRO.com
- Studies on Pipeline Antiretrovirals Reveal New Data on Possible Drug Interactions (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Switching to Tenofovir Increases Bone Turnover, Raltegravir Can Improve Bone Density (April 10, 2012)
From HIVandHepatitis.com
- Isentress for Four Years (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Raltegravir: Long-Term Results (February 2012)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
 Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
From TheBody.com
- Conference Update From IAS 2011: Medication News (September/October 2011)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Elvitegravir vs. Raltegravir: 48-Week Results in Treatment-Experienced Patients (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Raltegravir Still Effective at 5 Years (July 26, 2011)
From HIVandHepatitis.com
|
Advertisement
|
Email
Glossary
